Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT00047073

Sirolimus in Treating Patients With Glioblastoma Multiforme

A Modified Phase I/II Trial Of Rapamycin In Patients With Glioblastoma Multiforme

Sponsor: Jonsson Comprehensive Cancer Center

Conditions Brain and Central Nervous System Tumors

Interventions Rapamycin Supportive Care Surgery

Updated 7 times since 2017 Last updated: Jul 30, 2020 Started: Jul 31, 2002 Primary completion: Jun 30, 2005 Completion: Oct 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Brain and Central Nervous System Tumors and is currently completed. Jonsson Comprehensive Cancer Center leads this study, which shows 7 recorded versions since 2002 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Sep 2020 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Sep 2020 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Jul 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jonsson Comprehensive Cancer Center

Data source: Jonsson Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Los Angeles, United States